Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib

Cancer Res. 2010 Jun 1;70(11):4318-26. doi: 10.1158/0008-5472.CAN-09-4428. Epub 2010 May 11.

Abstract

Multiple pathways have been proposed to explain how proteasome inhibition induces cell death, but mechanisms remain unclear. To approach this issue, we performed a genome-wide siRNA screen to evaluate the genetic determinants that confer sensitivity to bortezomib (Velcade (R); PS-341). This screen identified 100 genes whose knockdown affected lethality to bortezomib and to a structurally diverse set of other proteasome inhibitors. A comparison of three cell lines revealed that 39 of 100 genes were commonly linked to cell death. We causally linked bortezomib-induced cell death to the accumulation of ASF1B, Myc, ODC1, Noxa, BNIP3, Gadd45alpha, p-SMC1A, SREBF1, and p53. Our results suggest that proteasome inhibition promotes cell death primarily by dysregulating Myc and polyamines, interfering with protein translation, and disrupting essential DNA damage repair pathways, leading to programmed cell death.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Boronic Acids / pharmacology*
  • Bortezomib
  • Cell Death / drug effects*
  • Cell Death / genetics
  • Colonic Neoplasms / drug therapy
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / pathology
  • DNA Damage
  • Gene Knockdown Techniques
  • HCT116 Cells
  • HeLa Cells
  • Humans
  • Intracellular Signaling Peptides and Proteins / genetics
  • Melanoma / drug therapy
  • Melanoma / genetics
  • Melanoma / metabolism
  • Melanoma / pathology
  • Protease Inhibitors / pharmacology*
  • Proteasome Inhibitors*
  • Protein Serine-Threonine Kinases / biosynthesis
  • Protein Serine-Threonine Kinases / genetics
  • Proto-Oncogene Proteins c-myc / biosynthesis
  • Proto-Oncogene Proteins c-myc / genetics
  • Pyrazines / pharmacology*
  • RNA, Small Interfering / genetics*
  • Ribosomes / drug effects
  • TOR Serine-Threonine Kinases
  • Transfection

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Intracellular Signaling Peptides and Proteins
  • MYC protein, human
  • Protease Inhibitors
  • Proteasome Inhibitors
  • Proto-Oncogene Proteins c-myc
  • Pyrazines
  • RNA, Small Interfering
  • Bortezomib
  • MTOR protein, human
  • Protein Serine-Threonine Kinases
  • TOR Serine-Threonine Kinases